tert-Butyl 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoate is a key intermediate in the synthesis of Lumacaftor (VX-809), a CFTR corrector used in combination therapies for the treatment of cystic fibrosis, particularly targeting the F508del mutation.

Its tert-butyl ester protecting group facilitates synthetic manipulation and improves solubility during drug development. The core structure, featuring a difluorobenzodioxole moiety linked via cyclopropanecarboxamide to a substituted pyridine-benzene system, enables specific interaction with the CFTR protein to promote proper folding and trafficking to the cell surface.

This compound is primarily employed in medicinal chemistry research for optimizing CFTR modulator potency, selectivity, and pharmacokinetic properties. It supports structure-activity relationship (SAR) studies aimed at enhancing efficacy in correcting defective chloride channel function in cystic fibrosis patients.